23 completed. 23 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 23 |
| Phase 1 | 1 | Completed 1 |
Follow Thymoma: new trials by email Literature Review of Thymoma trials Research Report on Thymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents Pembrolizumab, Lenvatinib 10 mg - Metastatic Thymic Carcinoma, Thymoma Type B3 | Phase 2 | Completed | MedSIR | 43 | 2021-09-21 | 2026-02-19 |
| A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma Atezolizumab - Carcinoma, Thymic | Phase 2 | Completed | Hoffmann-La Roche | 34 | 2020-08-07 | 2024-06-11 |
| Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery Carboplatin, Paclitaxel, Ramucirumab - Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma | Phase 2 | Completed | SWOG Cancer Research Network | 21 | 2019-03-20 | 2025-10-30 |
| Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy lucitanib 15 mg QD, lucitanib 10 mg QD, placebo QD - Advanced Thymic Carcinoma | Phase 2 | Completed | Haihe Biopharma Co., Ltd. | 74 | 2018-08-16 | 2026-09-17 |
| Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Vorolanib, Nivolumab - Thymic Carcinoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 88 | 2018-07-10 | 2024-10-08 |
| A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Sunitinib - Thymic Carcinoma | Phase 2 | Completed | Seoul National University Hospital | 25 | 2015-10-01 | 2019-01-23 |
| Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy Regorafenib - Pancreas Cancer, Ovarian Cancer | Phase 2 | Completed | Istituto Clinico Humanitas | 82 | 2014-12-01 | 2022-09-10 |
| A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas BKM120 - Thymoma | Phase 2 | Completed | Patrick Joseph Loehrer Sr. | 14 | 2014-10-01 | 2022-04-11 |
| Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Sunitinib - Thymoma, Thymus Neoplasms | Phase 2 | Completed | National Cancer Institute (NCI) | 56 | 2012-05-15 | 2024-09-24 |
| A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Amrubicin - Thymoma, Thymus Cancer | Phase 2 | Completed | Heather Wakelee | 33 | 2011-06-01 | 2019-04-16 |
| Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies AZD6244, MK-2206, Lapatinib - Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung | Phase 2 | Completed | National Cancer Institute (NCI) | 647 | 2011-02-08 | 2024-10-01 |
| Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Everolimus - Thymoma and Thymic Carcinoma | Phase 2 | Completed | Armando Santoro, MD | 41 | 2011-02-01 | 2022-09-10 |
| Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy IMC-12 - Thymoma, Thymic Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 49 | 2009-08-01 | 2016-12-23 |
| Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Belinostat (PDX101) - Thymoma, Thymic Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2007-12-01 | 2015-09-30 |
| Preoperative Treatment of Patients With High Risk Thymoma cisplatin and etoposide, Surgical Resection, Concurrent Radiotherapy - Thymoma | Phase 2 | Completed | Valley Health System | 21 | 2006-10-01 | 2014-12-09 |
| A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer bevacizumab, Erlotinib - Thymic Cancer, Thymoma | Phase 2 | Completed | Indiana University | 18 | 2006-08-01 | 2014-06-03 |
| Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma Octreotide - Thymoma | Phase 2 | Completed | Novartis Pharmaceuticals | 25 | 2005-09-01 | 2017-03-31 |
| Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Premetrexed (Alimta) - Thymoma, Thymic Carcinoma | Phase 2 | Completed | Patrick Joseph Loehrer Sr. | 27 | 2005-01-01 | 2019-07-22 |
| Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma carboplatin, paclitaxel - Thymoma, Thymic Carcinoma | Phase 2 | Completed | Eastern Cooperative Oncology Group | 46 | 2001-06-19 | 2023-06-29 |
| Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Imatinib mesylate - Life Threatening Diseases | Phase 2 | Completed | Novartis Pharmaceuticals | 185 | 2001-02-01 | 2016-11-18 |
Showing 20 of 23. Sign in to see all of them.
Small Cell Lung Carcinoma (4) · Carcinoma, Non-Small-Cell Lung (3) · Thymus Neoplasms (3) · Melanoma (2) · Neoplasm Metastasis (2) · Adenocarcinoma (1) · Anemia, Refractory (1) · Brenner Tumor (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Ductal, Breast (1) · Carcinoma, Renal Cell (1) · Chondrosarcoma (1) · Chordoma (1) · Dermatofibrosarcoma (1)
Hemic and Lymphatic Diseases (23) · Lymphatic Diseases (23) · Neoplasms by Histologic Type (23) · Neoplasms by Site (23) · Neoplasms, Complex and Mixed (23) · Thoracic Neoplasms (23) · Neoplasms (22) · Thymus Neoplasms (20) · Respiratory Tract Diseases (5) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4) · Respiratory Tract Neoplasms (4) · Lung Neoplasms (3) · Pathologic Processes (3)
Sunitinib (3) · Carboplatin (2) · Erlotinib Hydrochloride (2) · Octreotide (2) · Paclitaxel (2) · Taxes (2) · AZD 6244 (1) · Antilymphocyte Serum (1) · Bevacizumab (1) · Busulfan (1) · Cisplatin (1) · Cord Blood Stem Cell Transplantation (1) · Cyclophosphamide (1) · Cyclosporine (1) · E-3810 (1)
National Cancer Institute (NCI) (4) · Eastern Cooperative Oncology Group (2) · Novartis Pharmaceuticals (2) · Patrick Joseph Loehrer Sr. (2) · Armando Santoro, MD (1) · Haihe Biopharma Co., Ltd. (1) · Heather Wakelee (1) · Hoffmann-La Roche (1) · Indiana University (1) · Istituto Clinico Humanitas (1) · Jonsson Comprehensive Cancer Center (1) · MedSIR (1) · Roswell Park Cancer Institute (1) · SWOG Cancer Research Network (1) · Seoul National University Hospital (1)
United States (15) · Italy (3) · China (2) · Canada (1) · France (1) · Germany (1) · South Africa (1) · South Korea (1) · Spain (1)
Arun Rajan, M.D. (3) · Armando Santoro, MD (2) · Patrick Loehrer, M.D. (2) · Anne S Tsao (1) · Barbara Jean Bambach, MD (1) · Benjamin Besse, MD, PhD (1) · David S. Ettinger, MD (1) · Giuseppe Giaccone, M.D. (1) · Heather A. Wakelee (1) · Huiming Cai, MD (1) · Jong Seok Lee, MD, PhD (1) · Jordi Remon, MD, PhD (1) · Kathryn Beckermann, MD (1) · Michael Heinrich, MD (1)
PMID 14722038, PMID 18222230, PMID 19451433, PMID 20421818, PMID 21502553, PMID 21502559, PMID 24139613, PMID 24439931, PMID 25592632, PMID 25667274, PMID 26028668, PMID 26766736, PMID 27992479, PMID 29240542, PMID 31746632, PMID 32590747, PMID 34393061, PMID 36330484, PMID 40907517
P30CA016056 (1), U10CA021115 (1), U10CA180888 (1)